Skip to Main Content

Paper Details

Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
J Clin Oncol
8
2024
ATZ, Atezolizumab, DANTE, Docetaxel, EGA, Esophagogastric Cancer, FLOT, Fluorouracil, Leucovorin, Oxaliplatin, PD-L1, PD-L1 antibody, Patients, atezolizumab, docetaxel, esophagogastric adenocarcinoma, fluorouracil, leucovorin, oxaliplatin, patients, tumors
Author NameAffiliation
Timo GaiserInstitut fur Pathologie, Universitatsmedizin Mannheim
Timo GaiserInstitut fur Pathologie, Universitatsmedizin Mannheim
  • 1 - 2

Datasets

Release 1.2